|
1
|
Ralston SL, Lieberthal AS, Meissner HC,
Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa
NF, Mendonca EA, et al: Clinical practice guideline: The diagnosis,
management, and prevention of bronchiolitis. Pediatrics.
134:e1474–e1502. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bennett MV, Mclaurin K, Ambrose C and Lee
HC: Population-based trends and underlying risk factors for infant
respiratory syncytial virus and bronchiolitis hospitalizations.
PLoS One. 13(e0205399)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Oren E, Frere J and Yom-Tov E and Yom-Tov
E: Respiratory syncytial virus tracking using internet search
engine data. BMC Public Health. 18(445)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stein RT, Bont LJ, Zar H, Polack FP, Park
C, Claxton A, Borok G, Butylkova Y and Wegzyn C: Respiratory
syncytial virus hospitalization and mortality: Systematic review
and meta-analysis: Incidence of RSV hospitalization and mortality.
Pediatr Pulmonol. 52:556–569. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Goodwin E, Gilman MSA, Wrapp D, Chen M,
Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF,
et al: Infants infected with respiratory syncytial virus generate
potent neutralizing antibodies that lack somatic hypermutation.
Immunity. 48:339:–349.e5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Taleb SA, Al Thani AA, Al Ansari K and
Yassine HM: Human respiratory syncytial virus: Pathogenesis, immune
responses, and current vaccine approaches. Eur J Clin Microbiol
Infect Dis. 37:1817–1827. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Griffiths C, Drews SJ and Marchant DJ:
Respiratory syncytial virus: Infection, detection, and new options
for prevention and treatment. Clin Microbiol Rev. 30:277–319.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Meissner HC: Viral bronchiolitis in
children. N Engl J Med. 374:1793–1794. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wu X, Zhou X, Hu Y, Liu C and Wang J:
Neutralization of nerve growth factor (NGF) inhibits the Th2
response and protects against the respiratory syncytial virus (RSV)
infection. Immunol Res. 65:721–728. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hijano DR, Siefker DT, Bishwas S, Jaligama
S, Vu LD, Tillman H, Finkelstein D, Saravia J, You D and Cormier
SA: Type I interferon potentiates IgA immunity to respiratory
syncytial virus infection during infancy. Sci Rep.
8(11034)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
James KM, Gebretsadik T, Escobar GJ, Wu P,
Carroll KN, Li SX, Walsh EM, Mitchel EF, Sloan C and Hartert TV:
Risk of childhood asthma following infant bronchiolitis during the
respiratory syncytial virus season. J Allergy Clin Immun.
132:227–229. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang HL and Lü FF: Research advance of
association between viral bronchiolitis and asthma in children.
Chin J Pract Pediatr. 32:895–900. 2017.
|
|
13
|
Hall CB, Weinberg GA, Blumkin AK, Edwards
KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR,
Williams JV, et al: Respiratory syncytial virus-associated
hospitalizations among children less than 24 months of age.
Pediatrics. 132:e341–e348. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hislop AA: Airway and blood vessel
interaction during lung development. J Anat. 201:325–334.
2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ostadabbas S, Bulach C, Ku DN, Anderson LJ
and Ghovanloo M: A passive quantitative measurement of airway
resistance using depth data. Conf Proc IEEE Eng Med Biol Soc.
2014:5743–5747. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Stensballe LG, Kofoed PE, Nante EJ, Sambo
M, Jensen IP and Aaby P: Duration of secretory IgM and IgA
antibodies to respiratory syncytial virus in a community study in
Guinea-Bissau. Acta Paediatr. 89:421–426. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chu HY, Steinhoff MC, Magaret A, Zaman K,
Roy E, Longdon G, Formica MA, Walsh EE and Englund JA: Respiratory
syncytial virus transplacental antibody transfer and kinetics in
mother-infant pairs in Bangladesh. J Infect Dis. 210:1582–1589.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Johnson JE, Gonzales RA, Olson SJ, Wright
PF and Graham BS: The histopathology of fatal untreated human
respiratory syncytial virus infection. Mod Pathol. 20:108–119.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wollmeister E, Alvarez AE, Bastos JCS,
Marson FAL, Ribeiro JD, Baracat ECE, Arns CW and Riccetto AGL:
Respiratory syncytial virus in Brazilian infants-Ten years, two
cohorts. J Clin Virol. 98:33–36. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gadomski AM and Scribani MB:
Bronchodilators for bronchiolitis. Cochrane Database Syst Rev.
2014(CD001266)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mazur NI, Martinón-Torres F, Baraldi E,
Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H,
Papadopoulos NG, et al: Lower respiratory tract infection caused by
respiratory syncytial virus: Current management and new
therapeutics. Lancet Respir Med. 3:888–900. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
National Institute for Health and Care
Excellence: Bronchiolitis in children: diagnosis and
management|Guidance and guidelines NICE. Available from: urihttps://www.
nice.org.uk/guidance/NG9simplehttps://www.
nice.org.uk/guidance/NG9, 2015.
|
|
23
|
Israel S, Rusch S, DeVincenzo J, Boyers A,
Fok-Seang J, Huntjens D, Lounis N, Mariёn K, Stevens M and René
Verloes R: Effect of oral JNJ-53718678 (JNJ-678) on disease
severity in healthy adult volunteers experimentally inoculated with
live respiratory syncytial virus (RSV): A placebo-controlled
challenge study. Open Forum Infect Dis. 3 (Suppl 1)(S650)2016.
|
|
24
|
Xing Y and Proesmans M: New therapies for
acute RSV infections: Where are we? Eur J Pediatr. 178:131–138.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Guerguerian AM, Gauthier M, Lebel MH,
Farrell CA and Lacroix J: Ribavirin in ventilated respiratory
syncytial virus bronchiolitis. A randomized, placebo-controlled
trial. Am J Respir Crit Care Med. 160:829–834. 1999.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Manzoni P, Paes B, Lanctôt KL, Dall'Agnola
A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T and Li
A: Outcomes of infants receiving palivizumab prophylaxis for
respiratory syncytial virus in Canada and Italy: An international,
prospective cohort study. Pediatr Infect Dis J. 36:2–8.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Isaacs A and Baron S: Antiviral action of
interferon in embryonic cells. Lancet. 2:946–947. 1960.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Welliver RC Sr: The immune response to
respiratory syncytial virus infection: Friend or foe? Clin Rev
Allergy Immunol. 34:163–173. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Reassessment of the indications for
ribavirin therapy in respiratory syncytial virus infections.
American academy of pediatrics committee on infectious diseases.
Pediatrics. 97:137–140. 1996.
|
|
30
|
Bem RA, Domachowske JB and Rosenberg HF:
Animal models of human respiratory syncytial virus disease. Am J
Physiol Lung Cell Mol Physiol. 301:L148–L156. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Van-Schaik SM, Obot N, Enhorning G, Hintz
K, Gross K, Hancock GE, Stack AM and Welliver RC: Role of
interferon gamma in the pathogenesis of primary respiratory
syncytial virus infection in BALB/c mice. J Med Virol. 62:257–266.
2000.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wen S, Yu M, Zheng G, Lv F, Chen X, Lin L,
Li C and Zhang H: Changes in the etiology of viral lower
respiratory tract infections in hospitalized children in Wenzhou,
China: 2008-2017. J Med Virol. 92:982–987. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Glezen WP, Greenberg SB, Atmar RL, Piedra
PA and Couch RB: Impact of respiratory virus infections on persons
with chronic underlying conditions. JAMA. 283:499–505.
2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mori M, Morio T, Ito S, Morimoto A, Ota S,
Mizuta K, Lwata T, Hara T and Saji T: Risks and prevention of
severe RS virus infection among children with immunodeficiency and
Down's syndrome. J Infect Chemother. 20:455–459. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rostad CA: Respiratory syncytial virus:
Spectrum of clinical manifestations and complications in children.
Pediatr Ann. 48:e349–e353. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rahmati MB, Ahmadi M, Malekmohamadi
Hasanpur S, Zare SH and Jafari M: The significance of chest
ultrasound and chest X-ray in the diagnosis of children clinically
suspected of pneumonia. J Med Life. 8:50–53. 2015.PubMed/NCBI
|
|
37
|
Tai CC, Tsai CH, Huang YH, Lee CL, Chen HP
and Chan YJ: Detection of respiratory viruses in adults with
respiratory tract infection using a multiplex PCR assay at a
tertiary center. J Microbiol Immunol Infect, Aug 12, 2020 (Online
ahead of print).
|
|
38
|
Allen AJ, Gonzalez-Ciscar A, Lendrem C,
Suklan J, Allen K, Bell A, Baxter F, Crulley S, Fairlie L, Hardy D,
et al: Diagnostic and economic evaluation of a point-of-care test
for respiratory syncytial virus. ERJ Open Res. 6:00018–2020.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Alidjinou EK, Lefebvre N, Dewilde A, Mäki
M, Hober D and Engelmann I: Evaluation of the reverse transcription
strand invasion based amplification (RT-SIBA) RSV assay, a rapid
molecular assay for the detection of respiratory syncytial virus.
Diagn Microbiol Infect Dis. 95:55–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Percze K, Szakács Z, Scholz É, András J,
Szeitner Z, Kieboom CH, Ferwerda G, Jonge MI, Gyurcsányi RE and
Mészáros T: Aptamers for respiratory syncytial virus detection. Sci
Rep. 7(42794)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Leonardi GP, Wilson AM, Dauz M and Zuretti
AR: Evaluation of respiratory syncytial virus (RSV) direct antigen
detection assays for use in point-of-care testing. J Virol Methods.
213:131–134. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
McDonald JC and Quennec P: Utility of a
respiratory virus panel containing a monoclonal antibody pool for
screening of respiratory specimens in nonpeak respiratory syncytial
virus season. J Clin Microbiol. 10:2809–2811. 1993.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cilla G, Sarasua A, Montes M, Arostegui N,
Vicente D, Pérez-Yarza E and Pérez-Trallero E: Risk factors for
hospitalization due to respiratory syncytial virus infection among
infants in the Basque Country, Spain. Epidemiol Infect.
134:506–513. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shah BA, Singh G, Naik MA and Dhobi GN:
Bacteriological and clinical profile of community acquired
pneumonia in hospitalized patients. Lung India. 27:54–57.
2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
McIntosh K: Community acquired pneumonia
in children. New Engl J Med. 346:429–437. 2002.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gottschalk RA, Dorrington MG, Dutta B,
Krauss KS, Martins AJ, Uderhardt S, Chan WP, Tsang JS,
Torabi-Parizi P, Fraser ID and Germain RN: IFN-mediated negative
feedback supports bacteria class-specific macrophage inflammatory
responses. Elife. 8(e46836)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liu SY, Sanchez DJ and Cheng G: New
developments in the induction and antiviral effectors of type I
interferon. Curr Opin Immunol. 23:57–64. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Rath S and Padhy RN: Antibacterial
efficacy of five medicinal plants against multidrug-resistant
enteropathogenic bacteria infecting under-5 hospitalized children.
J Integr Med. 13:45–57. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Blonk B and Cock IE: Interactive
antimicrobial and toxicity profiles of Pittosporum angustifolium
Lodd. extracts with conventional antimicrobials. J Integr Med.
17:261–272. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Gut W, Pancer K, Abramczuk E, Cześcik A,
Dunal-Szczepaniak M, Lipka B and Litwińska B: RSV respiratory
infection in children under 5 y.o.-dynamics of the immune response
Th1/Th2 and IgE. Przegl Epidemiol. 67:17–22, 105-109.
2013.PubMed/NCBI(In English, Polish).
|
|
51
|
Cormier SA, Shrestha B, Saravia J, Lee GI,
Shen L, DeVincenzo JP, Kim YI and You D: Limited type I interferons
and plasmacytoid dendritic cells during neonatal respiratory
syncytial virus infection permit immunopathogenesis upon
reinfection. J Virol. 88:9350–9360. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sedeyn K, Schepens B and Saelens X:
Respiratory syncytial virus nonstructural proteins 1 and 2:
Exceptional disrupters of innate immune responses. PLoS Pathog.
15(e1007984)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hijano DR, Vu LD, Kauvar LM, Tripp RA,
Polack FP and Cormier SA: Role of type I interferon (IFN) in the
respiratory syncytial virus (RSV) immune response and disease
severity. Front Immunol. 10(566)2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Laura MS and Steven MV: Function and
modulation of type I interferons during respiratory syncytial virus
infection. Vaccines (Basel). 8(177)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Greenberg SB: Viral pneumonia. Infect Dis
Clin North Am. 5:603–621. 1991.PubMed/NCBI
|
|
56
|
von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: STROBE Initiative. The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. Lancet. 370:1453–1457. 2007.PubMed/NCBI View Article : Google Scholar
|
